Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.3900
Nov 17 • 3:59 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
-
Market Cap
2.96M
Enterprise Value
-11.32M
Income
-3.53M
Sales
0.00M
Book/sh
0.87
Cash/sh
1.88
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
4
IPO
Aug 22, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.45
P/C
0.21
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.85
Current Ratio
1.85
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.52
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
91.14% 78.52%
Sales past 3/5Y
- -
EPS Y/Y TTM
59.14%
Sales Y/Y TTM
-
EPS Q/Q
-90.80%
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
-150.00% -
Insider Own
14.97%
Insider Trans
0.00%
Inst Own
6.48%
Inst Trans
0.40%
ROA
-20.73%
ROE
-43.15%
ROIC
-53.58%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-2.03%
SMA50
-11.16%
SMA200
-40.11%
Trades
Shs Outstand
6.74M
Shs Float
6.45M
52W High
1.43 -72.73%
52W Low
0.35 11.33%
Volatility
9.25% 8.37%
ATR (14)
0.04
RSI (14)
44.53
Beta
2.15
Rel Volume
0.00
Avg Volume
32.50K
Volume
0
Perf Week
-13.45%
Perf Month
4.56%
Perf Quarter
-32.06%
Perf Half Y
-39.24%
Perf YTD
-60.24%
Perf Year
-66.38%
Perf 3Y
-99.52%
Perf 5Y
-99.98%
Perf 10Y
-
Prev Close
0.39
Price
0.39
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$500.00
Implied Upside
+128,105.1%
Analysts5incl. previous ratings
Rating Distribution5 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 18, 2021Initiated
BBTIG Research
Buy$11+2,720.5%
Oct 02, 2020Initiated
BB. Riley FBR
Buy$9+2,207.7%
Nov 20, 2019Initiated
CCantor Fitzgerald
Overweight$7+1,694.9%
Aug 13, 2019Initiated
HH.C. Wainwright
Buy$7+1,694.9%
Jun 21, 2019Initiated
CCantor Fitzgerald
Overweight$7+1,694.9%
Dec 21, 2017Initiated
OPY logoOOppenheimer
Outperform$18+4,515.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Herskowitz NeilDirectorDec 30 '25Sale0.96247238145Dec 30 04:17 PM
Chill Adam J.DirectorDec 30 '25Sale0.9544375Dec 30 04:16 PM
Jin DavidDirectorDec 30 '25Buy0.96247238286Dec 30 04:15 PM
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.
J.D.Mr. Michael S. Weiss Esq.
PresidentDr. Manuel Litchman M.D.
Controller & Interim Chief Accounting OfficerMr. Peter Carney
Chief Quality OfficerMr. Greg Furrow M.S.
Corporate SecretaryMs. Robyn M. Hunter